Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
almost like “we” knew it was coming
Something to think about. Using 'simple math'...
If IBIO didn't do the RSs, it would be a 0.0006 stock right now.
Whoever that idiot that was telling people to 'Buy Buy Buy' and average down, got clobbered.
The first split for IBIO took place on June 11, 2018. This was a 1 for 10 reverse split.
The second split took place on October 10, 2022. This was a 1 for 25 reverse split.
The third split took place on November 29, 2023. This was 1 for 20 reverse split.
Holy Dilution Batman!
After the RS, the OS was 1,405,036 shares and lookie how many IBIO trying to unload with the offering. Warrants exercisable immediately too.
As a result of the reverse split, the number of shares of the Company’s outstanding Common Stock will be reduced from 28,100,733 shares to 1,405,036 shares.
Up to 1,790,281 Shares of Common Stock
Up to 1,790,281 Series C Common Warrants to Purchase 1,790,281 Shares of Common Stock
Up to 1,790,281 Series D Common Warrants to Purchase 1,790,281 Shares of Common Stock
Up to 1,790,281 Pre-Funded Warrants to Purchase 1,790,281 Shares of Common Stock
Up to 5,370,843 Shares of Common Stock Underlying the Series C Common Warrants, Series D Common Warrants and Pre-Funded Warrants
Going Concern
Our management has concluded that substantial doubt exists about our ability to continue as a going concern for one year from the date of this prospectus. We do not expect that the net proceeds from this offering will be sufficient to allow us to continue as a going concern for one year from the date of this prospectus. If we were to receive gross proceeds of $3.5 million from this offering, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will meet our capital needs into the third quarter of fiscal year 2024. If we receive raise $7.0 million in gross proceeds through the sale of securities or otherwise throughout 2023, we believe that we will then meet our capital needs into the fourth quarter of fiscal 2024. However, if a sale of the CDMO Facility is not consummated prior to the December 31, 2023 maturity date of the term loan with Woodforest we will not have sufficient funds to repay the term loan on its maturity date, which term loan has an outstanding balance of $12.6 million as of September 30, 2023, in which case we anticipate negotiating with Woodforest a further amendment to the Credit Agreement while we search for a new purchaser of the CDMO Facility or conducting further offerings, both public and private, to repay the term loan and meet our capital needs. However, there can be no assurance that we will be successful in negotiating with Woodforest a further amendment to the Credit Agreement to extend out the maturity date and/or implementing any of the options that we are evaluating.
Using 'Simple Math' with rounded numbers
Authorized Shares: 275,000,000
Stock Price $0.20
20 to 1 RS = $4.00
Dilution Potential: $1B+
Oops they did it again...
They didn't do a proportional split on the AS.
Just like last RS IBIO will have plenty of shares once again to dilute.
On November 27, 2023, the Company approved a proposal at the Annual Meeting to amend the Company’s Certificate of Incorporation (the “Certificate of Incorporation”) to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a ratio between 1-for-5 to 1-for-20, with the ratio within such range to be determined at the discretion of the Company’s Board of Directors (the “Board”), without reducing the authorized number of shares of Common Stock.
What a beating IBIO took today.
The first split for IBIO took place on June 11, 2018. This was a 1 for 10 reverse split.
The second split took place on October 10, 2022. This was a 1 for 25 reverse split.
The third will take place on November 29, 2023. This will be a 1 for 20 reverse split.
Notice how they are coming quicker?
But wait, there is more...
Market Cap: $5.62 million
Guess what's next?
"The market capitalization rule is a rule set by the New York Stock Exchange (NYSE) to determine a minimum market value for a company to continue to be listed on the exchange. The market capitalization rule states that companies must maintain a minimum market cap of $15 million over a consecutive 30-day trading period."
20-to-1 reverse split in two days.
Let's see. If you bought a boat load of stock at $5, you needed the stock to get to $125 after the last RS to break even. After this one using simple math, you would need $2,500. Should there be a class action again the company and the IBIO stock pumper who pretends to be a stock analyst giving out financial advice without a license?
iBio Announces Reverse Stock Split - November 27 2023
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) effective at 12:01 a.m. ET on November 29, 2023 (the “Effective Date”). The Common Stock is expected to begin trading on a split-adjusted basis when the market opens on November 29, 2023, with the new CUSIP number 451033708.
The reverse stock split was authorized by iBio’s stockholders at the Company’s 2023 Annual Meeting, held earlier today, with a ratio ranging from 1-for-5 to 1-for-20 (the “Range”), with the ration within such Range to be determined at the discretion of the Company’s Board of Directors. As a result of the reverse stock split, every 20 shares of the Company's Common Stock issued and outstanding will be automatically combined into one share of common stock, with no change in the $0.0001 par value per share. Holders of fractional shares will be entitled to receive a cash payment equal to the number of shares of the Common Stock held by such stockholder before the reverse stock split that would otherwise have been exchanged for such fractional share interest multiplied by the average closing sales price of the Common Stock as reported on the NYSE American for the ten days preceding the Effective Date. As a result of the reverse split, the number of shares of the Company’s outstanding Common Stock will be reduced from 28,100,733 shares to 1,405,036 shares.
The exercise prices of all outstanding stock options, warrants, and equity incentive plans will be adjusted in accordance with their respective terms. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of the Company's shares with the exception of those holders of fractional shares.
The Company’s transfer agent, Continental Stock Transfer & Trust Company, which is also acting as the exchange agent for the reverse split, will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new certificates, should they wish to do so. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares.
https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/stock-news/92661398/ibio-announces-reverse-stock-split
What happened to the other moderator? The one who invested here at $125 and was continually recommending BUY! BUY! BUY! ???
I can understand how one's heart just isn't in it anymore, after losing that much MONI. Probably had crow instead of turkey over Thanksgiving.
Printing: $0.2526 - 52 week low for IBIO.
Isn't that an all time low for IBIO?
I did try to warn you.
Maybe they will need to do a bigger RS.
If the sp drops to $0.15, that would only be $3 with the max 1-for-20 RS.
Maybe they would go with a 1-for-40?
"to approve an amendment to the Company’s Certificate of Incorporation, in substantially the form attached to the accompanying proxy statement as Appendix A, at the discretion of the Board of Directors of the Company, to effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.001 per share (“Common Stock”), including stock held by the Company as treasury shares, at a ratio of 1-for-5 to 1-for-20 (the “Range”), with the ratio within such Range (the “Reverse Stock Split Ratio”) to be determined at the discretion of the Board and included in a public announcement, subject to the authority of the Board of Directors to abandon such amendment;"
That was a nice trick they did so IBIO could continue to dilute to the tune over 25x the OS. I would bet the upcoming RS will be at the top of the range to 1:20 so when they dilute, it will give them more time before the share price slips from $6 back to $0.03 again.
IBIO had zero revenue from continued operations and only $4.3M of cash left in of June. How much are they burning per month? Is it $1M I didn't look.
Using simple math if that is the case they are OOC (Out of Cash), with no other revenue. Yike! Now they need to go to shady LPC and deal with Dickie. Watch the shorting begin after the RS by you know who.
Revenue
"During the Fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated
$391,000 of its revenue reported in discontinued operations from four customers. During the Fiscal year ended June 30,
2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a
revenue contract and generated $499,000 of revenue reported in discontinued operations from eight customers. "
Reverse Stock Split
"On October 7, 2022, we effected a reverse stock split at a ratio of one-for-twenty five (1:25) shares of our common stock.
As a result of the reverse stock split, every twenty five (25) shares of the Company's common stock either issued and
outstanding or held by us in our treasury immediately prior to the effective time was, automatically and without any action
on the part of the respective holders thereof, combined and converted into one (1) share of our common stock. The reverse
split also applied to common stock issuable upon the exercise of our outstanding stock options. The reverse stock split did
not affect the par value of our common stock or the shares of our common stock that we are authorized to issue under our
Certificate of Incorporation, as amended. No fractional shares were issued in connection with the reverse stock split.
Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead
were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. All share and per share
amounts of common stock presented in this Annual Report have been retroactively adjusted to reflect the one-for-twenty
five reverse stock split."
https://ir.ibioinc.com/sec-filings##document-18796-0001420720-23-000062-2
I wonder if the authorized shares will remain unchanged like during the last reverse split. Wouldn't that be something?
BUY BUY BUY!!!
Buy all you can. When you mention to friends you bought at below 0.30, be sure to ignore the RS and tell the the current after-RS price to impress them and solidify your position as an investment GURU. LMAO
You called this RS many months ago. Spot on.
Where's the fake analyst when you need some commentary on this fantastic investment?
And there you go...
Yet another RS. For those that still can remember things, IBIO did a 1 for 25 a year ago on October 10th.
"...to approve an amendment to the Company’s Certificate of Incorporation, in substantially the form attached to the accompanying proxy statement as Appendix A, at the discretion of the Board of Directors of the Company, to effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.001 per share (“Common Stock”), including stock held by the Company as treasury shares, at a ratio of 1-for-5 to 1-for-20 (the “Range”), with the ratio within such Range (the “Reverse Stock Split Ratio”) to be determined at the discretion of the Board and included in a public announcement, subject to the authority of the Board of Directors to abandon such amendment;"
https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/stock-news/92285111/form-pre-14a-other-preliminary-proxy-statements
Up to Seven Amendments now...
A clear sign IBIO out of cash and needs to tap into Reserve Funds Deposit Account as they don't have enough MONey to make it to the end of the year.
On October 4, 2023, iBio CDMO
LLC (“Borrower”), a wholly owned subsidiary of iBio, Inc. (the
“Company”) and Woodforest National Bank (“Woodforest”) entered into
the Seventh Amendment to the Credit Agreement, which was entered
into on November 1, 2021, as previously amended as of October 11,
2022, February 9, 2023, February 20, 2023, March 24, 2023, May 10,
2023 and September 18, 2023 (the “Credit Agreement”), which
amendment among other things, permits the Company, in each case, so
long as no Potential Default or Default (as such terms are defined
in the Credit Agreement) to make the following withdrawals from the
Reserve Funds Deposit Account (as defined in the Credit Agreement):
(i) up to $1,000,000 on October 4, 2023 so long as Borrower
maintains a minimum balance of $2,000,000 until October 16, 2023,
(ii) up to an additional $750,000 after October 16, 2023 so long as
Borrower maintains a minimum balance of $1,250,000 until November
13, 2023, and (iii) up to an additional $250,000 after November 13,
2023 so long as Borrower maintains a minimum balance of $1,000,000
until Payment in Full (as defined in the Credit Agreement). On the
earlier of (a) the closing of the Purchase Agreement (as defined in
the Credit Agreement), or (b) the Maturity Date (as defined in the
Credit Agreement), the Company will pay Woodforest $20,000. In
addition, on October 4, 2023, the Company, as guarantor, entered
into the Fifth Amendment to the Guaranty, which was executed on
November 1, 2021, as amended by the Guaranty First Amendment, the
Guaranty Second Amendment, the Guaranty Third Amendment and the
Guaranty Fourth Amendment (the “Guaranty”), which amendment reduces
the liquidity covenant that requires the Company to maintain a
specified amount in unrestricted cash to $0.00.
The descriptions of the Seventh Amendment to the Credit Agreement and the Fifth Amendment to the Guaranty do not purport to be complete and are qualified in their entirety by reference to the Seventh Amendment to the Credit Agreement and the Fifth Amendment to the Guaranty, copies of which are filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
New Friday evening filing out. Nice try to bury it.
They got the form right...
Form POS AM - Post-Effective amendments for registration statement
https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/stock-news/92163208/form-pos-am-post-effective-amendments-for-regist
I forgot they had a shelf out there to dump $200M from 'time to time'. No wonder the stock tanked among other issues.
Remember, IBIO didn't RS the AS equally like they did the share price. IBIO has 275,000,000 AS. Pleny o room for dilution x10
But wait. There is more
The spruce goose isn't being sold for the $30M-$40M the fake stock analyst was saying...
"The Purchase and Sale Agreement provides that the Property will be sold to Majestic Realty for a purchase price of $17,250,000, or the Purchase Price."
All this was in the 10-K if anyone read it anyway.
Right, which is one reason I don't look at charts. They are always split adjusted. It's absolute garbage how they show it.
iBio Announces Filing of 2023 Annual Report on SEC Form 10-K - SEPTEMBER 27, 2023
BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the filing of its annual report on Form 10-K with the United States Securities and Exchange Commission ("SEC") for the fiscal year ended June 30, 2023
Revenues for the fiscal year ended June 30, 2023 were $nil, compared to $1.9 million in fiscal 2022. Total operating expenses, not including the loss from discontinued operations, were $29.3 million in fiscal 2023, a 7% decrease from $31.6 million in fiscal 2022. iBio's consolidated net loss for the fiscal year ended June 30, 2023 was $65.0 million, an increased loss of $14.6 million compared to 2022, due primarily to increased loss from discontinued operations. iBio held cash and cash equivalents of $4.3 million, and restricted cash of $3.3 million, as of June 30, 2023.
Pursuant to the disclosure requirements of the NYSE American Company Guidelines Sections 401(h) and 610(b), the Company advises that its audited financial statements for the fiscal year ended June 30, 2023, included in its annual report on Form 10-K filed today with the SEC, contained an audit opinion from its independent registered public accounting firm related to the Company’s ability to continue as a going concern. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph.
Subsequent to fiscal 2023 year end, iBio announced an amendment to its credit agreement (the “Credit Agreement”) with Woodforest National Bank (the “Agreement”), extending the Agreement’s maturity date from November 1, 2023 to the earlier of December 31, 2023 or the acceleration of maturity of the term loan in accordance with the Credit Agreement. The extension of the maturity date was intended to afford the Company sufficient time to close the pending sale of its cGMP biologics manufacturing facility (the “CDMO Facility”), which is anticipated to occur before the end of calendar 2023. There can be no assurance that the closing conditions for the sale of the CDMO Facility will be satisfied.
“Once the pending sale of the CDMO Facility closes, and the Woodforest loan is paid in full, for which there can be no assurance, it will complete the divestiture of iBio’s contract development and manufacturing business in Texas, and extend our cash runway to help support continued advancement of our AI drug discovery platform and immunotherapy pipeline out of our research and development center in California,” said Martin Brenner, DVM, Ph.D., iBio’s Chief Executive Officer and Chief Scientific Officer.
https://ir.ibioinc.com/news-events/press-releases/detail/211/ibio-announces-filing-of-2023-annual-report-on-sec-form-10-k
Charts go by those numbers. Just take a look. I see the stock over $125.
https://www.google.com/search?q=ibio+chart&rlz=1C1SQJL_enUS886US886&oq=ibio+chart&aqs=chrome..69i57j69i60l3.3639j0j4&sourceid=chrome&ie=UTF-8
You asked me who was recommending the stock at $125. I went back to pull the posts. I don't check the moron's posts. He's an idiot.
I have never seen anyone go by those numbers besides you, but to each their own.
If you have him on ignore, why do you check his messages? He can't talk to anybody here because nobody's here.
I have the fake stock analyst that is trying to con people on ignore. He's just s stock pumper after all and a bad one at that. You were asking about the $125 buys. You do realize if people say $5, it can mean different things pre or post split. Most people will factor in the splits when discussing share price or say post/presplit. The stock was at $5 multiple times due to reverse splits.
The fake stock analyst says he has a relationships with LPC too. IBIO's new piggybank. What what happens with this vulture funder.
Ok, but why not say $5, and why are you obsessed with the analyst? Just block him and be done with it.
If one bought at $5 like the 'stock analyst' before the 2nd reverse split, then that would have been $125 split adjusted.
iBio (IBIO) has 2 splits in our IBIO split history database. The first split for IBIO took place on June 11, 2018. This was a 1 for 10 reverse split, meaning for each 10 shares of IBIO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. IBIO's second split took place on October 10, 2022. This was a 1 for 25 reverse split, meaning for each 25 shares of IBIO owned pre-split, the shareholder now owned 1 share. For example, a 100 share position pre-split, became a 4 share position following the split.
Ouch, that was presplit so that would translate at $125.
Tuesday, July 28, 2020
Post# 24016 of 27379
picked up 4k at $5
good to go as this will move North nicely from LOD
Wednesday, October 12, 2022
Post# 26744 of 27378
averaging down here nicely....
ooRAH iBio...!
It's never been $125.
That was thrown around Stocktwits forever during Covid because delusional people thought it would go that high.
Who is it that recommended a buy at $125? How many years ago was that?
"averaging down here nicely....
ooRAH iBio...!"
It says 50 below the 15.
This is just a gutter stock that will die or one day we wake up and it's on the Moon. That's it, no in between... No hanging out at $5 for a while...
Who is it that recommended a buy at $125? How many years ago was that?
I think the minimums change a while ago during the Covid meltdown.
It's now $15M which they don't meet, now have no revenue and fired up the dilution machine with LPC which is a known vulture.
https://www.nyse.com/publicdocs/nyse/markets/nyse-american/MKT_Continued_Listing_Standards.pdf
'tutes' continue their dumping spree, even though the fake stock analyst recommended a buy at $125.
How does a garbage company like this manage to avoid being delisted for a Year? They have been well under the required $50 Million market cap for at least a Year.
Who was dumb enough to buy in the .40's premarket only to take a 25% haircut?
Was it the IBIO stock analyst?
iBio Announces Amendment to Credit Agreement with Woodforest - September 21 2023
https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/stock-news/92100093/ibio-announces-amendment-to-credit-agreement-with
Maybe they get a few million out of the spruce goose in Texas. That ought to last them a few more months.
Take a look at IBIO's pipeline. They have nothing in trials. Absolutely NOTHING. They are years and 100's of millions away from getting through to Phase III. The stock analyst has said that before.
https://ibioinc.com/pipeline/
If they do…
it won’t be toxic death spiral dilutive financing…
that evicerates all shareholders like your love interest Gerald does to his TOMDF beleaguered shareholders
dumptin’s up w/Ibio Buchweat
nuff said …!
MOO shill n tout
IBIO must be fix'n to raise more dough. Did they ever PR this? From 2023-08-14 or does retail not know yet?
"This prospectus relates to the offer and resale, from time to time, of up to 4,474,945 shares of our common stock"
Is that 20% more dilution?
Did IBIO ever sell their spruce goose in TX? The one the IBIO stock analyst was 100% wrong on. Interest payments now are escalating until they default on the loan.
https://www.sec.gov/Archives/edgar/data/1420720/000110465923091249/tm2322856-2_424b3.htm
SP usually pops for a few days to raise up the price while they dilute more. Traders making some bank. The moron stock analyst that loaded up at $125 lost his skirt.
IBIO must be fix'n to raise more dough. Did they ever PR this? From 2023-08-14 or does retail not know yet?
"This prospectus relates to the offer and resale, from time to time, of up to 4,474,945 shares of our common stock"
Is that 20% more dilution?
Did IBIO ever sell their spruce goose in TX? The one the IBIO stock analyst was 100% wrong on. Interest payments now are escalating until they default on the loan.
https://www.sec.gov/Archives/edgar/data/1420720/000110465923091249/tm2322856-2_424b3.htm
SP usually pops for a few days to raise up the price while they dilute more. Traders making some bank. The moron stock analyst that loaded up at $125 lost his skirt.